Floatz logo

Albuterol

Pompe Disease

National Taiwan University HospitalSmall moleculePhase 4 / ApprovedDormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Pompe Disease cohort.

View all 28

Same molecule, other indications

Albuterol is also rated in:

childhood onset asthmaDormant
BB
Indicative ·
65 / 100
View asset →
Dyspnea; AsthmaticDormant
BB
Indicative ·
65 / 100
View asset →
Obesity, ChildhoodDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →